ProQR Announces Japanese Axiomer(TM) Patent Upheld Following Opposition Against Its Leading IP Estate for ADAR-mediated RNA Editing
Stock Information for ProQR Therapeutics N.V.
Loading
Please wait while we load your information from QuoteMedia.
Please wait while we load your information from QuoteMedia.
Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.